The XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative (XOMAO) SEC filings page on Stock Titan is intended to organize regulatory documents related to XOMA Royalty’s preferred stock and broader capital structure. While no specific SEC filings are listed in the provided data, XOMA Royalty’s press releases describe a business model and transaction activity that are typically reflected in formal filings such as annual reports, quarterly reports, and registration statements.
XOMA Royalty characterizes itself as a biotechnology royalty aggregator that acquires potential future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. When it acquires these future economic rights, the seller receives non-dilutive, non-recourse funding. The company also explains that its portfolio consists of milestone and royalty rights associated with baskets of drug products in development, and that its assets are milestone and royalty rights tied to individual drug products.
For a security like XOMAO, which represents depositary shares of the 8.375% Series B Cumulative Perpetual Preferred Stock, SEC filings are the primary source for detailed terms of the preferred stock, including dividend provisions, ranking, and any redemption or liquidation preferences. In addition, XOMA Royalty’s acquisitions of companies such as HilleVax, LAVA Therapeutics, and Mural Oncology, along with royalty sharing transactions like the amended Takeda collaboration, are the types of material events that are generally described in current reports and periodic filings.
On Stock Titan, the XOMAO filings page can be used alongside XOMA Royalty’s public press releases to understand how the company reports its royalty and milestone portfolio, commercial assets such as VABYSMO, OJEMDA, MIPLYFFA, XACIATO vaginal gel 2%, IXINITY, and DSUVIA, and the impact of corporate transactions on its financial position. AI-powered summaries can help explain lengthy filings by highlighting sections that relate to preferred stock terms, royalty and milestone accounting, and the structure of acquisitions and royalty-sharing agreements.
Investors reviewing XOMAO may look to SEC documents for details on cumulative preferred dividend obligations, the relationship between the preferred stock and common equity, and disclosures about the risks and potential variability of royalty and milestone income. Combined with the company’s own explanatory notes on how it defines “portfolio” and “assets,” these filings provide a regulatory view of XOMA Royalty’s royalty aggregation strategy and the securities it has issued, including the Series B preferred stock represented by XOMAO.
XOMA Royalty Corp Schedule 13G: Woodline Partners reports passive ownership of 5.4% of Common Stock, representing 640,001 shares. The filing cites 11,915,730 shares outstanding as of March 25, 2026. The statement is signed by Erin Mullen on 05/15/2026.
XOMA Royalty Corp Schedule 13G: Woodline Partners reports passive ownership of 5.4% of Common Stock, representing 640,001 shares. The filing cites 11,915,730 shares outstanding as of March 25, 2026. The statement is signed by Erin Mullen on 05/15/2026.
XOMA Royalty Corporation reported Q1 2026 total income and revenues of $12.3 million, down from $15.9 million a year earlier as revenue from contracts with customers declined, partly offset by higher income from purchased receivables under the effective interest rate method.
Operating expenses rose to $12.8 million from $10.0 million, driven mainly by higher general and administrative costs and amortization of intangible assets, resulting in an operating loss of $0.5 million. Gains on acquisitions and investment income lifted net income to $4.5 million, compared with $2.4 million in Q1 2025. Basic earnings per share available to common stockholders were $0.18, with diluted earnings per share of $0.17.
XOMA ended the quarter with $138.7 million in cash, cash equivalents, and restricted cash and total assets of $271.9 million. Total liabilities were $159.0 million, including current and long-term debt of about $102.8 million, while stockholders’ equity increased to $92.9 million. Management concluded existing liquidity is sufficient to fund planned operations for at least one year.
XOMA Royalty Corporation reported Q1 2026 total income and revenues of $12.3 million, down from $15.9 million a year earlier as revenue from contracts with customers declined, partly offset by higher income from purchased receivables under the effective interest rate method.
Operating expenses rose to $12.8 million from $10.0 million, driven mainly by higher general and administrative costs and amortization of intangible assets, resulting in an operating loss of $0.5 million. Gains on acquisitions and investment income lifted net income to $4.5 million, compared with $2.4 million in Q1 2025. Basic earnings per share available to common stockholders were $0.18, with diluted earnings per share of $0.17.
XOMA ended the quarter with $138.7 million in cash, cash equivalents, and restricted cash and total assets of $271.9 million. Total liabilities were $159.0 million, including current and long-term debt of about $102.8 million, while stockholders’ equity increased to $92.9 million. Management concluded existing liquidity is sufficient to fund planned operations for at least one year.
Ligand Pharmaceuticals has filed a Schedule 13D after entering into a merger agreement to acquire XOMA Royalty Corporation. Through voting and support agreements, Ligand may be deemed to beneficially own 8,062,678 shares, or 47.0% of XOMA’s common stock on an as-converted basis.
Under the merger, each XOMA common share will be converted into the right to receive $39.00 in cash plus contingent value rights tied to a CVR Trust’s interest in RemainCo LLC. Series X preferred shares will receive equivalent consideration on an as-converted basis, and the issuer’s perpetual preferred stock will be redeemed with accrued and unpaid dividends before closing. The deal requires majority stockholder approval, antitrust clearance, completion of a holding company reorganization and a CVR spin structure, and carries a $40,000,000 termination fee for specified failure or superior proposal scenarios.
Ligand Pharmaceuticals has filed a Schedule 13D after entering into a merger agreement to acquire XOMA Royalty Corporation. Through voting and support agreements, Ligand may be deemed to beneficially own 8,062,678 shares, or 47.0% of XOMA’s common stock on an as-converted basis.
Under the merger, each XOMA common share will be converted into the right to receive $39.00 in cash plus contingent value rights tied to a CVR Trust’s interest in RemainCo LLC. Series X preferred shares will receive equivalent consideration on an as-converted basis, and the issuer’s perpetual preferred stock will be redeemed with accrued and unpaid dividends before closing. The deal requires majority stockholder approval, antitrust clearance, completion of a holding company reorganization and a CVR spin structure, and carries a $40,000,000 termination fee for specified failure or superior proposal scenarios.
XOMA Royalty Corp ownership disclosure: Vanguard Capital Management reported beneficial ownership of 613,458 shares of Common Stock, representing 5.15% of the class. The filing lists 63,662 shares as sole voting power and 613,458 shares as sole dispositive power. The filing is signed by Ashley Grim on 04/30/2026.
The statement clarifies holdings include securities held for Vanguard funds and managed accounts and attributes dispositive authority to Vanguard Capital Management and specified affiliates.
XOMA Royalty Corp ownership disclosure: Vanguard Capital Management reported beneficial ownership of 613,458 shares of Common Stock, representing 5.15% of the class. The filing lists 63,662 shares as sole voting power and 613,458 shares as sole dispositive power. The filing is signed by Ashley Grim on 04/30/2026.
The statement clarifies holdings include securities held for Vanguard funds and managed accounts and attributes dispositive authority to Vanguard Capital Management and specified affiliates.
BVF-managed funds updated their ownership and support for XOMA Royalty Corp amid its planned merger with Ligand Pharmaceuticals. BVF and affiliated entities report beneficial ownership of 2,590,303 XOMA common shares, representing about 21.4% of the 12,129,405 shares outstanding as of April 23, 2026.
Certain BVF reporting persons signed a Voting and Support Agreement to vote their shares in favor of the merger and related transactions, appointing Ligand as proxy and agreeing not to sell or transfer their shares or assert appraisal rights during the agreement’s term. They also hold 5,003 shares of Series X Preferred Stock, convertible into 5,003,000 common shares, currently constrained by a 19.99% beneficial ownership cap that they plan to seek to increase to 45% to allow full conversion and voting for stockholder approval.
BVF-managed funds updated their ownership and support for XOMA Royalty Corp amid its planned merger with Ligand Pharmaceuticals. BVF and affiliated entities report beneficial ownership of 2,590,303 XOMA common shares, representing about 21.4% of the 12,129,405 shares outstanding as of April 23, 2026.
Certain BVF reporting persons signed a Voting and Support Agreement to vote their shares in favor of the merger and related transactions, appointing Ligand as proxy and agreeing not to sell or transfer their shares or assert appraisal rights during the agreement’s term. They also hold 5,003 shares of Series X Preferred Stock, convertible into 5,003,000 common shares, currently constrained by a 19.99% beneficial ownership cap that they plan to seek to increase to 45% to allow full conversion and voting for stockholder approval.
XOMA Royalty Corporation completed its acquisition of Generation Bio through a tender offer and follow-on merger, paying $4.2913 in cash plus one contingent value right (CVR) per share. XOMA estimates the CVR proceeds at $0.81 per Generation Bio share, based on excess net cash at closing.
At expiration, 4,722,533 shares, about 70% of Generation Bio’s stock, were tendered and accepted. XOMA acquired Generation Bio’s remaining cash, de minimis assets, approximately $98.0 million of Section 174 tax deductions, and legacy lipid nanoparticle (LNP) assets tied in part to a collaboration with Moderna.
Generation Bio had previously received $40.0 million upfront and $7.5 million in prepaid research funding under the Moderna agreement and could earn up to approximately $1.8 billion in future milestones plus tiered royalties. XOMA does not expect the next $7.5 million option milestone or major target option exercises in the next 12 months.
XOMA Royalty Corporation completed its acquisition of Generation Bio through a tender offer and follow-on merger, paying $4.2913 in cash plus one contingent value right (CVR) per share. XOMA estimates the CVR proceeds at $0.81 per Generation Bio share, based on excess net cash at closing.
At expiration, 4,722,533 shares, about 70% of Generation Bio’s stock, were tendered and accepted. XOMA acquired Generation Bio’s remaining cash, de minimis assets, approximately $98.0 million of Section 174 tax deductions, and legacy lipid nanoparticle (LNP) assets tied in part to a collaboration with Moderna.
Generation Bio had previously received $40.0 million upfront and $7.5 million in prepaid research funding under the Moderna agreement and could earn up to approximately $1.8 billion in future milestones plus tiered royalties. XOMA does not expect the next $7.5 million option milestone or major target option exercises in the next 12 months.
XOMA Royalty Corporation agreed to be acquired by Ligand Pharmaceuticals in an all-cash merger. XOMA common stockholders will receive $39.00 per share in cash plus contingent value rights tied to potential proceeds from certain Janssen-related litigation, giving both immediate value and additional upside potential.
The deal values XOMA at approximately $739 million and represents about a 14% premium to its 30‑day volume‑weighted average price before announcement. XOMA’s Series X preferred shares will convert to common stock, while its perpetual preferred shares will be redeemed with accrued dividends. A holding company reorganization and CVR structure will be completed before closing, and key shareholders owning roughly 47% of XOMA’s shares have agreed to support the transaction.
XOMA Royalty Corporation agreed to be acquired by Ligand Pharmaceuticals in an all-cash merger. XOMA common stockholders will receive $39.00 per share in cash plus contingent value rights tied to potential proceeds from certain Janssen-related litigation, giving both immediate value and additional upside potential.
The deal values XOMA at approximately $739 million and represents about a 14% premium to its 30‑day volume‑weighted average price before announcement. XOMA’s Series X preferred shares will convert to common stock, while its perpetual preferred shares will be redeemed with accrued dividends. A holding company reorganization and CVR structure will be completed before closing, and key shareholders owning roughly 47% of XOMA’s shares have agreed to support the transaction.
XOMA Royalty Corp’s Chief Financial Officer, Jeffrey Trigilio, exercised Performance Stock Units into common shares. On April 20, 2026, 11,538 PSUs converted into 11,538 shares of common stock at a stated price of $0.00 per share.
Following the transaction, Trigilio directly held 103,906 shares of common stock and 126,924 Performance Stock Units. Each PSU represents a contingent right to receive one share of common stock, vesting only if the stock reaches specified price targets and he continues serving the company through each vesting date.
XOMA Royalty Corp’s Chief Financial Officer, Jeffrey Trigilio, exercised Performance Stock Units into common shares. On April 20, 2026, 11,538 PSUs converted into 11,538 shares of common stock at a stated price of $0.00 per share.
Following the transaction, Trigilio directly held 103,906 shares of common stock and 126,924 Performance Stock Units. Each PSU represents a contingent right to receive one share of common stock, vesting only if the stock reaches specified price targets and he continues serving the company through each vesting date.
XOMA Royalty Corp’s Chief Legal Officer, Maricel Perea Montano, exercised performance-based equity awards into common stock. On April 20, 2026, she converted 3,370 Performance Stock Units (PSUs) into 3,370 shares of common stock at a stated price of $0.00 per share.
Following the transaction, she directly holds 41,793 common shares. The PSU award was tied to XOMA’s share price, with each PSU representing a contingent right to one share that vests only if the stock reaches specified price levels and she continues in service. After this exercise, 37,074 PSUs remain outstanding for her, scheduled to expire on March 11, 2029.
XOMA Royalty Corp’s Chief Legal Officer, Maricel Perea Montano, exercised performance-based equity awards into common stock. On April 20, 2026, she converted 3,370 Performance Stock Units (PSUs) into 3,370 shares of common stock at a stated price of $0.00 per share.
Following the transaction, she directly holds 41,793 common shares. The PSU award was tied to XOMA’s share price, with each PSU representing a contingent right to one share that vests only if the stock reaches specified price levels and she continues in service. After this exercise, 37,074 PSUs remain outstanding for her, scheduled to expire on March 11, 2029.
XOMA Royalty Corp director and CEO Owen Hughes reported equity compensation activity and updated holdings. On April 20, 2026, he exercised 10,568 Performance Stock Units, receiving an equal number of shares of XOMA common stock at a stated price of $0.00 per share.
Following this transaction, he holds 191,264 shares of common stock directly and 295 shares of common stock indirectly through a 401(k) plan. He also reports 102,000 depositary shares of 8.375% Series B cumulative preferred stock and a remaining balance of 116,245 Performance Stock Units, each tied to future vesting based on stock price and continued service.
XOMA Royalty Corp director and CEO Owen Hughes reported equity compensation activity and updated holdings. On April 20, 2026, he exercised 10,568 Performance Stock Units, receiving an equal number of shares of XOMA common stock at a stated price of $0.00 per share.
Following this transaction, he holds 191,264 shares of common stock directly and 295 shares of common stock indirectly through a 401(k) plan. He also reports 102,000 depositary shares of 8.375% Series B cumulative preferred stock and a remaining balance of 116,245 Performance Stock Units, each tied to future vesting based on stock price and continued service.